Soc. Security Admin. Seeks Industry Help In Speeding Orphan Drug Coverage
This article was originally published in Pharmaceutical Approvals Monthly
Sponsors of drugs to treat disabling illnesses have an opportunity to work with the Social Security Administration to simplify eligibility determinations that could in turn make it easier for patients to obtain Medicare coverage for their treatments
You may also be interested in...
"Regulatory Predictability" Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
FDA's new leadership should focus on improving the "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 5
The Power Of The Open Public Hearing
The US FDA took three high profile applications to an external advisory committee meeting during the week of 8 May – and offered a very skeptical read on the approvability of each. All three won positive votes from the committees, in no small part thanks to the messages delivered during the Open Public Hearings.